Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Through this important initiative, Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in the Aptivate Champion Run
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Subscribe To Our Newsletter & Stay Updated